Cardiol Therapeutics (CRDL) details fireside chat at Canaccord Genuity event

Rhea-AI Filing Summary

Cardiol Therapeutics Inc., a foreign private issuer based in Oakville, Ontario, furnished a Form 6-K indicating it files annual reports on Form 40-F. The report primarily submits a news release announcing Cardiol’s participation in a fireside chat at Canaccord Genuity’s 45th Annual Growth Conference.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 08/11/2025 - 08:04 AM Learn about SEC filing dates

FAQ

What did Cardiol Therapeutics (CRDL) report in this Form 6-K?

Cardiol Therapeutics reported that it furnished a Form 6-K mainly to submit a news release. The release announces the company’s participation in a fireside chat at Canaccord Genuity’s 45th Annual Growth Conference on August 11, 2025.

What is the purpose of Cardiol Therapeutics’ August 2025 Form 6-K?

The August 2025 Form 6-K serves to furnish an exhibit containing a news release. That release states Cardiol Therapeutics will participate in a fireside chat at Canaccord Genuity’s 45th Annual Growth Conference, rather than providing financial results or major transaction details.

Which annual report form does Cardiol Therapeutics (CRDL) use?

Cardiol Therapeutics indicates it files annual reports under cover of Form 40-F. This designation confirms its status as a foreign private issuer that uses Canadian reporting standards while listing its securities in U.S. markets under applicable exchange rules.

What exhibit is attached to Cardiol Therapeutics’ August 2025 Form 6-K?

The filing attaches Exhibit 99.1, a news release dated August 11, 2025. The news release announces Cardiol Therapeutics’ participation in a fireside chat at Canaccord Genuity’s 45th Annual Growth Conference, highlighting a planned investor-focused appearance rather than operational updates.

Where is Cardiol Therapeutics Inc. headquartered according to this filing?

Cardiol Therapeutics is headquartered at 602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5. This address is listed as the company’s principal executive offices in the Form 6-K, confirming its Canadian base as a foreign private issuer.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated August 11, 2025 - Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: August 11, 2025	By:	/s/ Chris Waddick
		Chris Waddick
	Title:	Chief Financial Officer